Organisation paid for research Program year 2021 Source: CMS Open Payments

NewPhase Clinical Trials Corp

Neither a doctor nor a teaching hospital

Research payments

$581,923

421 payments

Through program year 2021, NewPhase Clinical Trials Corp is reported as receiving $581,923 in research payments, across 421 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$169,912	22
2020	Research	$152,605	43
2019	Research	$259,407	356

Breakdown

Who paid Research payments · program years 2019–2021

Akebia Therapeutics Inc $469,298 399 payments
Pfizer Inc. $112,625 22 payments

Studies the money was for Research payments · program years 2019–2021

Akb-6548-Ci-0017 $120,079 199 payments
Akb-6548-Ci-0017 $72,088 2 payments
A 16Week Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Or Diet and Exercise $69,264 14 payments
Akb-6548-Ci-0015 $64,868 66 payments
Akb-6548-Ci-0016 $50,682 66 payments
A 16Week Phase 2 Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin $43,362 8 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $41,956 14 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $32,653 12 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction Or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate - Correction/Conversion) $22,372 6 payments
Akb-6548-Ci-0014 $17,486 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.